[Survival of cancer patients in Navarre and comparison with Spain].
Journal
Anales del sistema sanitario de Navarra
ISSN: 2340-3527
Titre abrégé: An Sist Sanit Navar
Pays: Spain
ID NLM: 9710381
Informations de publication
Date de publication:
16 Aug 2023
16 Aug 2023
Historique:
medline:
21
8
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
epublish
Résumé
To analyze the survival of adult cancer patients in Navarre, describe its trend, and compare the data for this Spanish Autonomous Community against that reported for Spain. Records of adult cancer patients were retrieved from the Navarre´s population-based cancer registry for two periods (1999-2007 and 2008-2016). The vital status had been updated to 2020. Observed survival, net survival and age-standardized net survival at five years with 95% confidence intervals were estimated overall and for twenty-nine cancer groups. We analyzed 57,564 cases. Age-standardized net survival was 59.9% (59.1-60.8) and 63.8% (62.8-64.7) for males and females diagnosed with cancer during the 2008-2016 period, respectively. Age-standardized net survival ranged from 13.4% (10.4-17.4) for pancreatic cancer to 94.0% (88.1-100) for thyroid cancer in male patients, and from 11.9% (7.2-19.7) for liver cancer to 95.6% (92.6-98.6-%) for thyroid cancer in female patients. Compared with cases diagnosed in the 1999-2007 period, age-standardized net survival increased in 10 cancer groups, resulting in an overall increase of 5.1 (4.1-6.0) percentage points. The age-standardized net survival in Navarre was 2.7 (1.9-3.4) percentage points higher than that described for Spain for the 2008-2013 period. In Navarre, the survival of cancer patients diagnosed during the 2008-2016 period improved significantly in comparison to the 1999-2007 period. Different factors may explain this improvement, including earlier diagnoses, more effective treatment options, and better healthcare processes. Overall, survival was higher in women than in men. Our results suggest a higher survival rate in Navarre than in Spain.
Sections du résumé
BACKGROUND
BACKGROUND
To analyze the survival of adult cancer patients in Navarre, describe its trend, and compare the data for this Spanish Autonomous Community against that reported for Spain.
METHODS
METHODS
Records of adult cancer patients were retrieved from the Navarre´s population-based cancer registry for two periods (1999-2007 and 2008-2016). The vital status had been updated to 2020. Observed survival, net survival and age-standardized net survival at five years with 95% confidence intervals were estimated overall and for twenty-nine cancer groups.
RESULTS
RESULTS
We analyzed 57,564 cases. Age-standardized net survival was 59.9% (59.1-60.8) and 63.8% (62.8-64.7) for males and females diagnosed with cancer during the 2008-2016 period, respectively. Age-standardized net survival ranged from 13.4% (10.4-17.4) for pancreatic cancer to 94.0% (88.1-100) for thyroid cancer in male patients, and from 11.9% (7.2-19.7) for liver cancer to 95.6% (92.6-98.6-%) for thyroid cancer in female patients. Compared with cases diagnosed in the 1999-2007 period, age-standardized net survival increased in 10 cancer groups, resulting in an overall increase of 5.1 (4.1-6.0) percentage points. The age-standardized net survival in Navarre was 2.7 (1.9-3.4) percentage points higher than that described for Spain for the 2008-2013 period.
CONCLUSIONS
CONCLUSIONS
In Navarre, the survival of cancer patients diagnosed during the 2008-2016 period improved significantly in comparison to the 1999-2007 period. Different factors may explain this improvement, including earlier diagnoses, more effective treatment options, and better healthcare processes. Overall, survival was higher in women than in men. Our results suggest a higher survival rate in Navarre than in Spain.
Identifiants
pubmed: 37594062
pii: e1042
doi: 10.23938/ASSN.1042
pmc: PMC10498136
doi:
pii:
Types de publication
English Abstract
Journal Article
Langues
spa
Sous-ensembles de citation
IM
Références
Eur J Cancer Care (Engl). 2019 Jul;28(4):e13043
pubmed: 30993764
Cancers (Basel). 2022 May 15;14(10):
pubmed: 35626046
IARC Sci Publ. 1991;(95):159-76
pubmed: 1894319
Eur J Cancer. 2015 Oct;51(15):2120-2129
pubmed: 26421816
Int J Cancer. 2018 Sep 1;143(5):1114-1127
pubmed: 29607493
Eur J Cancer. 2004 Oct;40(15):2307-16
pubmed: 15454257
Biometrics. 2012 Mar;68(1):113-20
pubmed: 21689081
IARC Sci Publ. 2011;(162):7-13
pubmed: 21675401
Tumori. 2010 Jul-Aug;96(4):i-A32
pubmed: 20968151
Ann Oncol. 2010 May;21 Suppl 3:iii21-29
pubmed: 20427356
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Health Rep. 2016 Apr;27(4):19-27
pubmed: 27096620
Eur J Cancer. 2009 Mar;45(5):747-55
pubmed: 19117750
Clin Transl Oncol. 2019 May;21(5):621-629
pubmed: 30341474
An Sist Sanit Navar. 2007 Sep-Dec;30(3 Suppl):419-58
pubmed: 18368729
Eur J Cancer. 2015 Oct;51(15):2130-2143
pubmed: 26421817
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Nat Rev Clin Oncol. 2019 Nov;16(11):684-701
pubmed: 31278397
Eur J Cancer Prev. 2017 Sep;26 Joining forces for better cancer registration in Europe:S215-S222
pubmed: 28914693
Eur J Cancer. 2007 Jan;43(1):149-60
pubmed: 17084622
Lancet Oncol. 2019 Nov;20(11):1493-1505
pubmed: 31521509
Endocrinol Diabetes Nutr. 2017 Jun - Jul;64(6):303-309
pubmed: 28604340
Eur J Cancer Prev. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries:S16-S23
pubmed: 28005601
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s41-s46
pubmed: 29700092
Leukemia. 2017 Mar;31(3):593-601
pubmed: 27568522
Clin Transl Oncol. 2018 Feb;20(2):201-211
pubmed: 28718071
Eur J Cancer. 2009 Apr;45(6):1017-27
pubmed: 19109009